Top 100 Most-Cited Papers in Herpes Zoster from 2000 to 2022: A Bibliometric Study

References

• De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29(3):695–747. doi:10.1128/CMR.00102-15
   PubMed Web of Science ®Google Scholar
• Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996;9(3):361–381. doi:10.1128/CMR.9.3.361
   PubMed Web of Science ®Google Scholar
• Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management. Viruses. 2022;14(2):1–13. doi:10.3390/v14020192
   Web of Science ®Google Scholar
• Sampathkumar P, Drage LA, Martin DP. Herpes zoster (Shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009;84(3):274–280. doi:10.4065/84.3.274
   PubMed Web of Science ®Google Scholar
• Dai Y, Yeh F, Shen Y, et al. Cigarette smoking and risk of herpes zoster: a population-based cohort study in Taiwan. Clin Exp Dermatol. 2021;46(7):1293–1298. doi:10.1111/ced.14650
   PubMed Web of Science ®Google Scholar
• United States Centers for Disease Control and Prevention. Shingles Surveillance. Available from: http://www.cdc.gov/shingles/surveillance.html. Accessed October 22, 2022.
   Google Scholar
• Zhang J, Ding Q, Li XL, Hao YW, Yang Y. Support vector machine versus multiple logistic regression for prediction of postherpetic neuralgia in outpatients with herpes zoster. Pain Physician. 2022;25(3):E481–8.
   PubMed Web of Science ®Google Scholar
• Kreitzer JM, Freedman G. Postherpetic Neuralgia. N Engl J Med. 2014;371(16):1526–1533. doi:10.1056/NEJMcp1403062
   PubMed Web of Science ®Google Scholar
• Drolet M, Brisson M, Schmader K, et al. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain. 2010;11(11):1211–1221. doi:10.1016/j.jpain.2010.02.020
   PubMed Web of Science ®Google Scholar
• Sun X, Wei Z, Lin H, Jit M, Li Z, Fu C. Incidence and disease burden of herpes zoster in the population aged ≥50 years in China: data from an integrated health care network. J Infect. 2021;82(2):253–260. doi:10.1016/j.jinf.2020.12.013
   PubMed Web of Science ®Google Scholar
• Schmidt-Ott R, Schutter U, Simon J, et al. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: a prospective study. J Infect. 2018;76(5):475–482. doi:10.1016/j.jinf.2018.02.001
   PubMed Web of Science ®Google Scholar
• Werner RN, Nikkels AF, Marinović B, et al. European consensus-based (S2k) guideline on the management of herpes zoster – guided by the European dermatology forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: treatment. J Eur Acad Dermatology Venereol. 2017;31(1):20–29. doi:10.1111/jdv.13957
   PubMed Web of Science ®Google Scholar
• Rodríguez-Jiménez P, Chicharro P, Cabrera LM, et al. Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: report of 5 cases. JAAD Case Reports. 2021;12:58–59. doi:10.1016/j.jdcr.2021.04.014
   PubMedGoogle Scholar
• Gershon AA, Breuer J, Cohen JI, et al. Varicella zoster virus infection. Nat Rev Dis Prim. 2015;1:15016. doi:10.1038/nrdp.2015.16
   PubMed Web of Science ®Google Scholar
• Van Noorden R, Maher B, Nuzzo R. The top 100 papers. Nature. 2014;514(7524):550–553. doi:10.1038/514550a
   PubMed Web of Science ®Google Scholar
• Agarwal A, Durairajanayagam D, Tatagari S, et al. Bibliometrics: tracking research impact by selecting the appropriate metrics. Asian J Androl. 2016;18(2):296–309. doi:10.4103/1008-682X.171582
   PubMed Web of Science ®Google Scholar
• Zhang L, Hou Y, Sun J, Zeng Y. The top 100 most cited articles in the last two decades of atopic dermatitis: a bibliometric analysis. Front Immunol. 2022;13:949665. doi:10.3389/fimmu.2022.949665
   PubMed Web of Science ®Google Scholar
• Xiao P, Yao C, Wang G. The top 100 most cited papers on endometrial carcinoma: a bibliometric analysis. Front Oncol. 2022;12:987980. doi:10.3389/fonc.2022.987980
   PubMedGoogle Scholar
• Zhang GF, Gong WX, Xu ZY, Guo Y. Alzheimer’s disease and epilepsy: the top 100 cited papers. Front Aging Neurosci. 2022;14:926982. doi:10.3389/fnagi.2022.926982
   PubMed Web of Science ®Google Scholar
• Chen JW, Guan Y, Zheng YL, Zhu K. Research trends and frontiers in exercise for movement disorders: a bibliometric analysis of global research from 2010 to 2021. Front Aging Neurosci. 2022;14:1–16.
   Web of Science ®Google Scholar
• Liu X, Hu X, Yu X, et al. Frontiers and hotspots of 18F-FDG PET/CT radiomics: a bibliometric analysis of the published literature. Front Oncol. 2022;12:965773. doi:10.3389/fonc.2022.965773
   PubMed Web of Science ®Google Scholar
• Gao M, Zhang H, Gao Z, et al. Global hotspots and prospects of perimenopausal depression: a bibliometric analysis via CiteSpace. Front Psychiatry. 2022;13:968629. doi:10.3389/fpsyt.2022.968629
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–2284. doi:10.1056/NEJMoa051016
   PubMed Web of Science ®Google Scholar
• Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494–500. doi:10.1016/j.coi.2012.06.002
   PubMed Web of Science ®Google Scholar
• Levin MJ, Weinberg A. Immune responses to zoster vaccines. Hum Vaccines Immunother. 2019;15(4):772–777.
   PubMed Web of Science ®Google Scholar
• Curran D, Kim JH, Matthews S, et al. Recombinant zoster vaccine is efficacious and safe in frail individuals. J Am Geriatr Soc. 2021;69(3):744–752. doi:10.1111/jgs.16917
   PubMed Web of Science ®Google Scholar
• Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022;386(23):2188–2200. doi:10.1056/NEJMoa2116620
   PubMed Web of Science ®Google Scholar
• Schmader KE, Levin MJ, Gnann JW, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis. 2012;54(7):922–928. doi:10.1093/cid/cir970
   PubMed Web of Science ®Google Scholar
• Drolet M, Brisson M, Schmader KE, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. C Can Med Assoc J. 2010;182(16):1731–1736. doi:10.1503/cmaj.091711
   PubMed Web of Science ®Google Scholar
• Drolet M, Levin MJ, Schmader KE, et al. Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine. 2012;30(12):2047–2050. doi:10.1016/j.vaccine.2012.01.045
   PubMed Web of Science ®Google Scholar
• Schmader KE, Sloane R, Pieper C, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007;23(6):490–496. doi:10.1097/AJP.0b013e318065b6c9
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster downloaded from S2 • CID 2007:44 (Suppl 1) • Dworkin et al. Clin Infect Dis. 2007;44(Suppl 1):1–26. doi:10.1086/510206
   PubMed Web of Science ®Google Scholar
• Le P, Rothberg M. Herpes zoster infection. BMJ. 2019;364:k5095. doi:10.1136/bmj.k5095
   PubMed Web of Science ®Google Scholar
• Yu Z, Zhao Y, Jin J, Zhu J, Yu L, Han G. Antiviral treatment in outpatients with herps zoster in six major areas of China, 2010–2019. Front Public Health. 2022;10:942377. doi:10.3389/fpubh.2022.942377
   PubMed Web of Science ®Google Scholar
• De Clercq E, Field HJ. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol. 2006;147(1):1–11. doi:10.1038/sj.bjp.0706446
   PubMed Web of Science ®Google Scholar
• De Clercq E. The discovery of antiviral agents: ten different compounds, ten different stories. Med Res Rev. 2008;28(6):929–953. doi:10.1002/med.20128
   PubMed Web of Science ®Google Scholar
• Schoenberger SD, Kim SJ, Thorne JE, et al. Diagnosis and treatment of acute retinal necrosis: a report by the American Academy of ophthalmology. Ophthalmology. 2017;124(3):382–392. doi:10.1016/j.ophtha.2016.11.007
   PubMed Web of Science ®Google Scholar
• Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to Acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev. 2003;16(1):114–128. doi:10.1128/CMR.16.1.114-128.2003
   PubMed Web of Science ®Google Scholar
• Höglund M, Ljungman P, Weller S. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. J Antimicrob Chemother. 2001;47(6):855–861. doi:10.1093/jac/47.6.855
   PubMed Web of Science ®Google Scholar
• McKendrick MW, McGill JI, White JE, Wood MJ. Oral Acyclovir in acute herpes zoster. Br Med J. 1986;293(6561):1529–1532. doi:10.1136/bmj.293.6561.1529
   PubMedGoogle Scholar
• Degreef H; Famciclovir Herpes Zoster Clinical Study Group. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents. 1994;4(4):241–246. doi:10.1016/0924-8579(94)90024-8
   PubMed Web of Science ®Google Scholar
• Barnabas RV, Baeten JM, Lingappa JR, et al. Acyclovir prophylaxis reduces the incidence of herpes zoster among HIV-infected individuals: results of a randomized clinical trial. J Infect Dis. 2016;213(4):551–555. doi:10.1093/infdis/jiv318
   PubMed Web of Science ®Google Scholar
• Peng Q, Guo X, Luo Y, et al. Dynamic Immune Landscape and VZV-Specific T cell responses in patients with herpes Zoster and Postherpetic Neuralgia. Front Immunol. 2022;13:887892. doi:10.3389/fimmu.2022.887892
   PubMed Web of Science ®Google Scholar
• Levin MJ, Oxman MN, Zhang JH, et al. Veterans affairs cooperative studies program shingles prevention study investigators. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197(6):825–835. doi:10.1086/528696
   PubMed Web of Science ®Google Scholar
• Lecrenier N, Beukelaers P, Colindres R, et al. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. Expert Rev Vaccines. 2018;17(7):619–634. doi:10.1080/14760584.2018.1495565
   PubMed Web of Science ®Google Scholar
• Levin MJ, Anderson JP, Seage GR, Williams PL. PACTG/IMPAACT 219C Team. Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children. J Acquir Immune Defic Syndr. 2009;50(2):182–191. doi:10.1097/QAI.0b013e31819550a4
   PubMed Web of Science ®Google Scholar
• Wang Y, Qi J, Cao H, Liu C. Immune responses to varicella-zoster virus glycoprotein E Formulated with Poly(Lactic-co-Glycolic Acid) nanoparticles and nucleic acid adjuvants in mice. Virol Sin. 2021;36(1):122–132. doi:10.1007/s12250-020-00261-y
   PubMed Web of Science ®Google Scholar
• Lu PJ, Hung MC, Srivastav A, et al. Surveillance of vaccination coverage among adult populations -United States, 2018. MMWR Surveill Summ. 2021;70(3):1–26. doi:10.15585/mmwr.ss7003a1
   PubMed Web of Science ®Google Scholar
• Sun Y, Huang L, Nie J, Feng K, Liu Y, Bai Z. Development of a perfusion process for serum-free adenovirus vector herpes zoster vaccine production. AMB Express. 2022;12(1):58. doi:10.1186/s13568-022-01398-7
   PubMed Web of Science ®Google Scholar
• Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet. 1974;2(7892):1288–1290. doi:10.1016/S0140-6736(74)90144-5
   PubMed Web of Science ®Google Scholar
• Harpaz R, Ortega-Sanchez IR, Seward JF. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). prevention of herpes zoster: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2008;57(RR–5):1–30.
   PubMedGoogle Scholar
• Merck Sharp & Dohme Corp. Zostavax (zoster vaccine, live) [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; 2009. Available from: http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm132831.pdf. Accessed January 25, 2011.
   Google Scholar
• Baxter R, Bartlett J, Fireman B, et al. Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study. Am J Epidemiol. 2018;187(1):161–169. doi:10.1093/aje/kwx245
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–2096. doi:10.1056/NEJMoa1501184
   PubMed Web of Science ®Google Scholar
• Bruxvoort KJ, Qian L, Wu J, et al. Herpes zoster following recombinant zoster vaccine with or without concomitant vaccination. Open Forum Infect Dis. 2022;9(3):ofac011. doi:10.1093/ofid/ofac011
   PubMed Web of Science ®Google Scholar
• Dooling KL, Guo A, Patel M, et al. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103–108. doi:10.15585/mmwr.mm6703a5
   PubMed Web of Science ®Google Scholar
• Duchon JM, Levin MJ, Gershon AA. Safety and varicella outcomes in in utero-exposed newborns and preterm infants treated with varicella zoster immune globulin (VARIZIG): a subgroup analysis of an expanded-access program. J Pediatric Infect Dis Soc. 2020;9(4):449–453. doi:10.1093/jpids/piz070
   PubMed Web of Science ®Google Scholar
• Zaia JA, Levin MJ, Preblud SR, et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis. 1983;147(4):737–743. doi:10.1093/infdis/147.4.737
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Updated recommendations for use of VariZIG--United States, 2013. MMWR Morb Mortal Wkly Rep. 2013;62(28):574–576.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Schmidt-Hieber M, Bertz H, et al. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol. 2016;95(9):1435–1455. doi:10.1007/s00277-016-2711-1
   PubMed Web of Science ®Google Scholar
• Nagel MA, Gilden D. Neurological complications of varicella zoster virus reactivation. Curr Opin Neurol. 2014;27(3):356–360. doi:10.1097/WCO.0000000000000092
   PubMed Web of Science ®Google Scholar
• Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med. 2014;371(16):1526–1533.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Ling DY, Zhang J, Wu Q, Zhang ZW, Wang ZY. Effectiveness of acupuncture therapy for postherpetic neuralgia: an umbrella review protocol. BMJ Open. 2021;11(5):e043064. doi:10.1136/bmjopen-2020-043064
   PubMed Web of Science ®Google Scholar
• Gross GE, Eisert L, Doerr HW, et al. S2k guidelines for the diagnosis and treatment of herpes zoster and postherpetic neuralgia. J Dtsch Dermatol Ges. 2020;18(1):55–78.
   Web of Science ®Google Scholar
• Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. doi:10.1136/bmjopen-2014-004833
   PubMed Web of Science ®Google Scholar
• Saguil A, Kane S, Mercado M, Lauters R. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician. 2017;96(10):656–663.
   PubMed Web of Science ®Google Scholar
• Li H, Ding Y, Zhu Y, Han Z, Yao P. Effective treatment of postherpetic neuralgia at the first branch of the trigeminal nerve by high-voltage pulsed radiofrequency. Front Neurol. 2021;12:746035. doi:10.3389/fneur.2021.746035
   PubMed Web of Science ®Google Scholar
• Nahm FS, Kim SH, Kim HS, et al. Survey on the treatment of postherpetic neuralgia in Korea; multicenter study of 1414 patients. Korean J Pain. 2013;26(1):21–26. doi:10.3344/kjp.2013.26.1.21
   PubMedGoogle Scholar
• Klompas M, Kulldorff M, Vilk Y, Bialek SR, Harpaz R. Herpes zoster and postherpetic neuralgia surveillance using structured electronic data. Mayo Clin Proc. 2011;86(12):1146–1153. doi:10.4065/mcp.2011.0305
   PubMed Web of Science ®Google Scholar
• Yang F, Yu S, Fan B, et al. The epidemiology of herpes zoster and postherpetic neuralgia in China: results from a cross-sectional study. Pain Ther. 2019;8(2):249–259. doi:10.1007/s40122-019-0127-z
   PubMed Web of Science ®Google Scholar
• Choo PW, Galil K, Donahue JG, Walker AM, Spiegelman D, Platt R. Risk factors for postherpetic neuralgia. Arch Intern Med. 1997;157(11):1217–1224. doi:10.1001/archinte.1997.00440320117011
   PubMedGoogle Scholar
• Zheng S, Lei M, Bai F, Tian Z, Wang H. The curative effect of pregabalin in the treatment of postherpetic neuralgia analyzed by deep learning-based brain resting-state functional magnetic resonance images. Contrast Media Mol Imaging. 2022;2022:2250621. doi:10.1155/2022/2250621
   PubMed Web of Science ®Google Scholar
• Kramer S, Baeumler P, Geber C, et al. Somatosensory profiles in acute herpes zoster and predictors of postherpetic neuralgia. Pain. 2019;160(4):882–894. doi:10.1097/j.pain.0000000000001467
   PubMed Web of Science ®Google Scholar
• Wang C, Yuan F, Cai L, Lu H, Chen G, Zhou J. Ultrasound-guided stellate ganglion block combined with extracorporeal shock wave therapy on postherpetic neuralgia. J Healthc Eng. 2022;2022:9808994. doi:10.1155/2022/9808994
   PubMed Web of Science ®Google Scholar
• Yang F, Liao P, You Y, Liang Y, Hu Y. The effectiveness of repetitive paravertebral block with ropivacaine and dexmedetomidine for the prevention of postherpetic neuralgia in patients with acute herpes zoster. Postepy Dermatol Alergol. 2022;39(1):116–120. doi:10.5114/ada.2021.106021
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Schmader KE. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis. 2003;36(7):877–882. doi:10.1086/368196
   PubMed Web of Science ®Google Scholar
• Ji M, Yao P, Han Z, Zhu D. Pulsed radiofrequency combined with methylene blue paravertebral nerve block effectively treats thoracic postherpetic Neuralgia. Front Neurol. 2022;13:811298. doi:10.3389/fneur.2022.811298
   PubMed Web of Science ®Google Scholar
• Moore A, Derry S, Wiffen P. Gabapentin for chronic neuropathic pain. JAMA. 2018;319(8):818–819. doi:10.1001/jama.2017.21547
   PubMed Web of Science ®Google Scholar
• Bookwalter T, Gitlin M. Gabapentin-induced neurologic toxicities. Pharmacotherapy. 2005;25(12I):1817–1819. doi:10.1592/phco.2005.25.12.1817
   PubMedGoogle Scholar
• Bansal D, Bhansali A, Hota D, Chakrabarti A, Dutta P. Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. Diabet Med. 2009;26(10):1019–1026. doi:10.1111/j.1464-5491.2009.02806.x
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O’Connor AB, Kent J, et al. Interventional management of neuropathic pain: neuPSIG recommendations. Pain. 2013;154(11):2249–2261. doi:10.1016/j.pain.2013.06.004
   PubMed Web of Science ®Google Scholar
• Zhu J, Luo G, He Q, Yao M. Evaluation of the efficacy of unipolar and bipolar spinal dorsal root ganglion radiofrequency thermocoagulation in the treatment of postherpetic neuralgia. Korean J Pain. 2022;35(1):114–123. doi:10.3344/kjp.2022.35.1.114
   PubMed Web of Science ®Google Scholar
• NIH Consensus Conference. Acupuncture. JAMA. 1998;280(17):1518–1524. doi:10.1001/jama.280.17.1518
   PubMed Web of Science ®Google Scholar
• Pei W, Zeng J, Lu L, Lin G, Ruan J. Is acupuncture an effective postherpetic neuralgia treatment? A systematic review and meta-analysis. J Pain Res. 2019;12:2155–2165. doi:10.2147/JPR.S199950
   PubMed Web of Science ®Google Scholar